Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy

Not Applicable

Withdrawn

• Conditions: Type 1 Diabetes

• Registration Number: NCT04284033
• Lead Sponsor: Stanford University

Brief Summary

This is a randomized trial to determine if an extended wear infusion set can be worn for up to 7 days with a hybrid closed-loop system in adult with Type 1 Diabetes

Detailed Description

This study will compare use of a standard infusion set with an extended wear infusion set. Subjects will be asked to wear both types of sets twice for up to 7 days, alternating wear of set type over 4 weeks. The order of infusion set wear will be randomized with the first set wear. The investigators aim to see whether there is a benefit to using an extended wear infusion set.

Study Timeline

• Study Start: 2017-02-14
• Primary Completion: 2017-11-10
• Study Completion: 2018-04-20
• Study First Submitted: 2020-02-22
• Study First Submitted QC: 2020-02-22
• Study First Posted: 2020-02-25
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-29
• Last Update Posted: 2021-09-02

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Clinical diagnosis of type 1 diabetes for more than one year, using an insulin infusion pump for at least 6 months, and using the 670G pump for at least 3 months
2. Age ≥18 years
3. Using Novolog or Humalog insulin at time of enrollment
4. For females, not currently known to be pregnant
5. An understanding of and willingness to follow the protocol and sign the informed consent
6. Willing to have photographs taken of their infusion sites
7. Willing to download their 670G pump every week to a research Carelink account
8. Willing to submit a brief online questionnaire at the time of any infusion set failure
9. Able to understand spoken or written English
10. Hemoglobin A1c <8.5% at the time of enrollment
11. Willing to perform three or more fingerstick glucose measurements each day
12. Willing to sign a consent for release of medical information at the time of enrollment
13. Willing to change their infusion pump insulin reservoirs at least every 6 days

Exclusion Criteria

1. Hypoglycemic seizure or loss of consciousness in the past 6 months
2. Severe episode of DKA in the 6 months prior to study enrollment that was unrelated to an infusion set failure
3. A known cardiovascular disease
4. Active proliferative diabetic retinopathy
5. Known tape allergy
6. Current treatment for a seizure disorder
7. Cystic fibrosis
8. Active infection
9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol
10. Inpatient psychiatric treatment in the past 6 months
11. Presence of a known adrenal disorder
12. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the last 2 months prior to enrollment in the study
13. Abuse of alcohol
14. History of dialysis, renal failure or known eGFR <60 ml/min/1.73m2
15. Has received a blood transfusion or required treatment for anemia in the three months prior to enrollment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Number of infusion set failures due to "unexplained hyperglycemia"	14 days for each type of infusion set, with each type of infusion set worn twice	Defined as: 1. Glucose \>250 mg/dL with failure of a correction dose to lower the glucose by 50 mg/dL; 2. Ketones ≥0.6 mg/dL with a glucose reading of \>250 mg/dL (in the absence of illness); 3. Evidence of infection at the infusion site (erythema or induration \>1cm in diameter); 4. Pump occlusion alarm

Secondary Outcome Measures

Name	Time	Method
Duration of infusion set wear	14 days for each type of infusion set, with each type of infusion set worn twice	The maximum number of days that 75% of the infusion sets are still working, excluding those that kinked on insertion or were accidentally pulled out.

Trial Locations

Locations (1)

Stanford University; 🇺🇸 Palo Alto, California, United States